hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06332313 id: 2023/10/05 briefTitle: Erector Spina Plane Block Volume Comparison overallStatus: NOT_YET_RECRUITING date: 2024-06-12 date: 2024-11-20 date: 2024-12-05 date: 2024-03-27 date: 2024-03-27 name: Kahramanmaras Sutcu Imam University class: OTHER briefSummary: After obtaining ethical committee approval from Kahramanmaras University Anesthesiology and Reanimation Department and Urology Clinic, 60 patients between 18-65 years old who meet ASA I-II classification criteria with body mass index ≤40 will be informed about this study both verbally and in writing prior to their inclusion in this study using a randomization method according to Helsinki Declaration after obtaining their written consent. Patients who cannot give consent due to any reason or have allergy history against local anesthetics or contraindications for peripheral nerve blocks (local infection,coagulopathy etc.) or psychiatric disorders or receiving antipsychotic drugs will be excluded from this study. Routine preoperative evaluation including age, height, and weight measurements will be performed on all patients at pre-anesthesia clinic.
Patients will be randomized into three groups: Group K, who will receive analgesia with patient-controlled analgesia (PCA) with tramadol only; Group E20, who will receive PCA with 20cc volume of ESP block; and Group E30, who will receive PCA with 30cc volume of ESP block. After standard general anesthesia induction and endotracheal intubation, one of the three analgesic methods will be randomly applied, and the surgery will commence. All patients will receive patient-controlled analgesia. Patients in Group K will not receive any local anesthetic injection. When the patient is transferred to the postoperative care unit, intravenous PCA device will be attached, and pain scores using Visual Analog Scale (VAS), rated from 0 (no pain) to 10 (worst pain ever experienced), at rest and during coughing will be evaluated at 2, 4, 6, 12, 18, and 24 hours postoperatively. The values will be recorded. When the patient experiences pain, analgesic agents will be administered according to the patient-controlled analgesia protocol. The time of first analgesic requirement and total amount of consumed analgesic agent within 24 hours will be recorded. Postoperative QUIPS: Quality Improvement in Postoperative Pain Management questionnaire will be administered, and side effects such as nausea/vomiting or sedation will be noted. Additionally, patient satisfaction regarding these methods and their willingness for repeat surgery or recommendation level on a scale from poor to excellent (very poor/poor/fair/good/excellent)will also be evaluated and recorded conditions: Pain, Postoperative studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 60 type: ESTIMATED name: erector spina plane block measure: The aim is to observe the difference in tramadol consumption within the first 24 hours after surgery in 3 groups. sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06332300 id: ADBL-LC-003 briefTitle: An Exploratory Clinical Study of Adebelimumab in Combination With Famitinib and Chemotherapy in Patients With NSCLC overallStatus: RECRUITING date: 2024-02-01 date: 2025-02-01 date: 2026-02-01 date: 2024-03-27 date: 2024-03-27 name: Jiangsu Province Nanjing Brain Hospital class: OTHER briefSummary: This study was a single-arm design to explore the efficacy and safety of Adebelimumab in combination with famitinib and lateral ventricular chemotherapy in patients with floppy meningeal metastases from non-squamous NSCLC who have failed EGFR-TKI therapy, and included patients with pathologically confirmed non-squamous non-small cell lung cancer. conditions: NSCLC studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 28 type: ESTIMATED name: Adebelimumab+Famitinib + FOLFIRI+Ariely measure: ORR measure: iPFS measure: iDoR measure: PFS measure: OS sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Shengcun Fang status: RECRUITING city: Nanjing state: Jiangsu country: China name: Shengcun Fang, PhD role: CONTACT phone: +86 13404163638 email: Fang1984@aliyun.com name: Jian Zhang, Master role: CONTACT phone: +86 13095457871 email: 919939410@qq.com lat: 32.06167 lon: 118.77778 hasResults: False
nctId: NCT06332287 id: 2023-NSCLC briefTitle: A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Advanced NSCLC With Leptomeningeal Metastasis overallStatus: RECRUITING date: 2023-05-01 date: 2024-11-01 date: 2025-06-01 date: 2024-03-27 date: 2024-03-27 name: Jiangsu Province Nanjing Brain Hospital class: OTHER briefSummary: To observe the efficacy of Trilaciclib combined with lateral ventricular chemotherapy in the treatment of non-small cell lung cancer with leptomeningeal metastasis。 conditions: NSCLC studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Trilaciclib primaryPurpose: TREATMENT masking: NONE count: 25 type: ESTIMATED name: combination of Trilaciclib and Pemetrexed measure: Duration of severe neutropenia (DSN) measure: Incidence of Treatment-Emergent Adverse Events measure: Incidence of grade 3 and 4 hematologic toxicity measure: Incidence of G-CSF treatment measure: Incidence of platelet transfusion sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fang Shencun status: RECRUITING city: Suzhou state: Jiangsu zip: 210029 country: China name: fang S cun, M.D. role: CONTACT phone: 83728558 phoneExt: 025 email: fang1984@aliyun.com lat: 31.30408 lon: 120.59538 hasResults: False
nctId: NCT06332274 id: 2023-503316-33-00 id: 2023/3720 type: OTHER domain: CSET number briefTitle: tislelizUMaB in canceR Patients With molEcuLar residuaL Disease acronym: UMBRELLA overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2028-05 date: 2029-04 date: 2024-03-27 date: 2024-03-27 name: Gustave Roussy, Cancer Campus, Grand Paris class: OTHER name: BeiGene name: C2i Genomics briefSummary: Numerous studies have shown that even when imaging does not reveal the presence of cancer cells, traces of tumor DNA (i.e. originating from cancer cells) can be detected in the blood of certain patients: this is called molecular residual disease (MRD). When such traces are detected (we speak of MRD+ status), the risk of relapse is much higher than when there is no circulating tumor DNA (MRD - status). Given the success of immunotherapy in treating patients with metastatic disease in a variety of tumor types, there is enormous enthusiasm for expanding the use of immunotherapy to people with cancer at an early stage.
UMBRELLA is a biology-driven trial designed to study the impact of systemic treatment with tislelizumab monotherapy after detection of MRD+ status after completion of surgery and perioperative treatments in patients with cancer of a solid tumor. Residual disease (MRD) will be determined by optimized detection and precise monitoring of circulating tumor DNA, enabling early detection of recurrence and disease monitoring, including in patients without MRD \[MRD(-)\]. conditions: Cancer conditions: Lung Cancer conditions: Colo-rectal Cancer conditions: Pancreas Cancer conditions: Soft Tissue Sarcoma studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: This is a double-blinded, randomized, placebo-controlled, multi-center, national, Phase 3 biology-driven trial designed to investigate the impact of systemic treatment with tislelizumab or placebo following detection of MRD minimum 3 months and maximum 4.5 months after completion of curative-intent therapy. primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 717 type: ESTIMATED name: Tislelizumab name: Blood sampling name: Placebo measure: Efficacy of tislelizumab compared to placebo as measured by DFS (Disease-free survival) measure: Estimation of DFS in subjects without MRD measure: Estimation of overall survival (OS) measure: Percentage of MRD (+) subject's completion of standard curative-intent therapy measure: Time between detection of MRD and detection of relapse at imaging. measure: Percentage of subjects with MRD assessment failure. measure: Estimation of the time to become MRD (-) for MRD(+) patients measure: Evaluation of Health-Related Quality of Life (QLQ) by QLQ-C30 measure: Evaluation of Health-Related Quality of Life (QLQ) by EQ-5D-5L measure: Cost effectiveness analysis: incremental cost measure: Cost effectiveness analysis: QALY measure: Cost effectiveness analysis: ICER sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Gustave Roussy city: Villejuif state: Val De Marne zip: 94800 country: France lat: 48.7939 lon: 2.35992 hasResults: False
nctId: NCT06332261 id: 2024-BB-01 briefTitle: Standardized Assessment in Depression Treatment in Routine Psychiatric Services overallStatus: ACTIVE_NOT_RECRUITING date: 2024-03-08 date: 2024-04 date: 2024-04 date: 2024-03-27 date: 2024-03-27 name: Karolinska Institutet class: OTHER name: Region Stockholm briefSummary: The goal of this observational study is to evaluate current practices in depression treatment in psychiatric services in Stockholm, Sweden.
Data will be collected retrospectively from medical records of patients having received psychological or pharmacological treatment for depression from 2020 to 2023. Frequency of standardized assessments (not scores) using the Montgomery-Åsberg Depression Rating Scale, the Montgomery-Åsberg Depression Rating Scale-Self Assessment, and the Patient Health Questionnaire-9 is collected, together with information on patient, clinician, and treatment characteristics. conditions: Major Depressive Disorder studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 4000 type: ESTIMATED measure: Montgomery-Åsberg Depression Rating Scale measure: Montgomery-Åsberg Depression Rating Scale-Self Assessment measure: The Patient Health Questionnaire-9 sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Stockholm Health Care Services, Region Stockholm city: Stockholm country: Sweden lat: 59.33258 lon: 18.0649 hasResults: False
nctId: NCT06332248 id: 2014/1023-31/4 & 2014/274-31/5 briefTitle: Possible Effects of the Dietary Supplement Magnesium Compared to Placebo overallStatus: COMPLETED date: 2014-09-15 date: 2015-05-20 date: 2015-05-28 date: 2024-03-27 date: 2024-03-27 name: Dan Hasson class: OTHER name: Stiftelsen Stressmottagningen name: AFA Insurance briefSummary: The goal of this clinical trial was to investigate possible outcomes of the nutritional supplement magnesium compared to placebo in healthy, working adults. The main questions it aimed to answer were:
Researchers compared the group ingesting magnesium with the group ingesting placebo pills to see if there were any differences in for example self-rated health, recovery, wellbeing, etc. conditions: Health Promotion studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Participants received either 375 mg nutritional supplement magnesium or placebo pill. primaryPurpose: SUPPORTIVE_CARE masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 1013 type: ACTUAL name: Magnesium name: Placebo measure: Time x group difference in HealthWatch-11 (questionnaire) measure: Intervention compliance measure 1 (objective, number of pills left) measure: Intervention compliance measure 2 (subjective, marked days in calendar) measure: Time x group difference in Oldenburg Burnout Inventory (questionnaire) measure: Time x group difference in Karolinska Sleep Questionnaire measure: Time x group difference in Pure Tone Audiogram (clinical hearing test) measure: Time x group difference in Speech in noise test (clinical hearing test) measure: Time x group difference in Uncomfortable loudness level (clinical hearing test) measure: Time x group difference in single questionnaire item assessing sick leave measure: Time x group difference in single questionnaire item assessing sickness presenteeism measure: Time x group difference in prevalence of pain (questionnaire) measure: Time x group difference in pain frequency (questionnaire) measure: Time x group difference in pain discomfort (questionnaire) measure: Time x group difference in pain intensity (questionnaire) measure: Time x group difference in functional impairment due to pain (questionnaire) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06332235 id: KMUHIRB-F(I)-20220023 briefTitle: Efficacy and Safety of Silodosin in the Treatment of Lower Urinary Tract Symptoms in Taiwanese Population. overallStatus: RECRUITING date: 2022-02-18 date: 2024-09-30 date: 2024-12-31 date: 2024-03-27 date: 2024-03-27 name: Kaohsiung Medical University Chung-Ho Memorial Hospital class: OTHER briefSummary: To evaluate the therapeutic effects and safety of silodosin in the patients of acute brain injury with lower urinary tract symptoms. conditions: Human Trichinellosis studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: PROSPECTIVE count: 70 type: ESTIMATED name: Silodosin 8 mg measure: Assessment criteria Efficacy measure: Assessment criteria Safety measure: Assessment criteria Efficacy sex: ALL minimumAge: 20 Years maximumAge: 100 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Kaohsiung Medical University Chung-Ho Memorial Hospital status: RECRUITING city: Kaohsiung state: Sanmin District zip: 807 country: Taiwan name: Chen Yu Chen, MS role: CONTACT phone: 0911884597 email: jennis7995@hotmail.com lat: 22.61626 lon: 120.31333 hasResults: False
nctId: NCT06332222 id: 1987 briefTitle: Recovery With Tart Cherry Supplementation Following a Marathon. overallStatus: COMPLETED date: 2023-04-01 date: 2023-10-11 date: 2023-10-11 date: 2024-03-27 date: 2024-03-27 name: Northumbria University class: OTHER name: Iprona Lana SpA briefSummary: The goal of this clinical trial is to compare recovery in healthy, active runners.
* blood samples conditions: Exercise Recovery studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: BASIC_SCIENCE masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 35 type: ACTUAL name: Tart Cherry name: Placebo measure: Maximal Voluntary Contraction measure: Counter Movement Jump measure: Active Muscle Soreness measure: Serum Concentration of High-Sensitive C-Reactive Protein measure: Serum Concentration of Creatine Kinase measure: Perceptual Measures sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Northumbria University city: Newcastle Upon Tyne state: Tyne And Wear zip: NE1 8ST country: United Kingdom lat: 54.97328 lon: -1.61396 hasResults: False
nctId: NCT06332209 id: Pro00135303 id: U66RH31458 type: OTHER_GRANT domain: Telehealth Center of Excellence briefTitle: Randomized Trial of Tele Vs. Clinic TF-CBT in Puerto Rico overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2025-09-30 date: 2025-09-30 date: 2024-03-27 date: 2024-03-29 name: Medical University of South Carolina class: OTHER briefSummary: The current study will evaluate TF-CBT delivered via tele-health for youth presenting with trauma symptoms via a randomized controlled trial. Goals of the current study are to examine the effectiveness of Tele-TF-CBT delivered by community providers in Puerto Rico in improving youth trauma outcomes. Goals are also to support the feasibility, acceptability, and engagement outcomes of Tele-health delivery. conditions: Post-Traumatic Stress Disorder studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 80 type: ESTIMATED name: Trauma Focused Cognitive Behavioral Therapy measure: Traumatic Stress Symptoms measure: Traumatic Stress Symptoms measure: Anxiety and Depression Symptoms measure: Anxiety and Depression Symptoms sex: ALL minimumAge: 7 Years maximumAge: 18 Years stdAges: CHILD stdAges: ADULT hasResults: False
nctId: NCT06332183 id: ECDGWAS briefTitle: GWAS and EWAS in Patients With Erdheim-Chester Disease overallStatus: RECRUITING date: 2019-07-17 date: 2024-07-01 date: 2024-10-01 date: 2024-03-27 date: 2024-03-27 name: Augusto Vaglio class: OTHER briefSummary: Erdheim-Chester Disease (ECD) is a rare form of histiocytosis characterized by the proliferation of blood cells, known as histiocytes, which infiltrate various organs and tissues, often causing irreversible damage. The causes of the condition are still unknown, and although some mutations in genes involved in cell proliferation have been identified, other factors may be involved. Susceptibility to developing rare diseases like ECD is typically associated with genetic factors, including DNA polymorphisms and epigenetic modifications.
This study aims to analyze the entire genome of a large cohort of patients with ECD and healthy controls to determine whether there are polymorphisms and epigenetic variants associated with susceptibility to developing the disease. The study could thus clarify the genetic predisposition to ECD development, provide insights into disease pathogenic mechanisms, and identify proteins or cellular mechanisms potentially targeted by specific treatments. conditions: Erdheim-Chester Disease studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 300 type: ESTIMATED name: Presence of polymorphisms measure: Polymorphisms and genetic variants correlated with disease development measure: Methylation in Erdheim-Chester disease measure: Gene expression in Erdheim-Chester disease sex: ALL minimumAge: 1 Year maximumAge: 99 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Hopital Pitié Salpetrière status: RECRUITING city: Paris country: France name: Julien Haroche role: CONTACT lat: 48.85341 lon: 2.3488 facility: Meyer Children's Hospital IRCCS status: RECRUITING city: Florence country: Italy name: Augusto Vaglio role: CONTACT email: augusto.vaglio@meyer.it lat: 43.77925 lon: 11.24626 facility: IRCCS Ospedale San Raffaele status: RECRUITING city: Milano country: Italy name: Lorenzo Dagna role: CONTACT lat: 45.46427 lon: 9.18951 facility: AOU Parma status: RECRUITING city: Parma country: Italy name: Davide Martorana role: CONTACT lat: 44.79935 lon: 10.32618 facility: Genetics Lab, CSIC status: RECRUITING city: Granada country: Spain name: Javier Martin role: CONTACT lat: 37.18817 lon: -3.60667 hasResults: False
nctId: NCT06332170 id: HS-20093-103 briefTitle: ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors overallStatus: NOT_YET_RECRUITING date: 2024-05-30 date: 2026-05-30 date: 2028-05-30 date: 2024-03-27 date: 2024-03-27 name: Hansoh BioMedical R&D Company class: INDUSTRY briefSummary: HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. The objectives of this study are to investigate the safety, tolerability, pharmacokinetics and anti-tumor activity of HS-20093 in combination with other anti-cancer agents in patients with advanced solid tumor patients. conditions: Advanced Solid Tumor studyType: INTERVENTIONAL phases: PHASE1 allocation: NON_RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: NONE count: 610 type: ESTIMATED name: HS-20093 name: Adebrelimab name: Cisplatin/ Carboplatin name: Cetuximab name: Enzalutamide measure: Maximum tolerated dose (MTD) for combination-treatments measure: Incidence and severity of adverse events (AEs) measure: Objective response rate (ORR) determined by investigators measure: Disease control rate (DCR) determined by investigators measure: Duration of response (DoR) determined by investigators measure: Progression-free survival (PFS) determined by investigators according to RECIST 1.1 measure: Overall survival (OS) measure: Radiographic progression-free survival (rPFS) determined by investigators according to RECIST 1.1 and PCWG3 measure: Time to PSA progression (TTPP) measure: Prostate-specific cancer antigen (PSA) response rate measure: Time to first subsequent therapy (TFST) measure: Observed maximum plasma concentration (Cmax) of HS-20093advanced solid tumor measure: Time to reach maximum plasma concentration (Tmax) of HS-20093 measure: Terminal half-life (T1/2) of HS-20093 following the first dose measure: Area under plasma concentration versus time curve from zero to last sampling time (AUC0-t) following the first dose of HS-20093 measure: Percentage of participants with antibodies to HS-20093 in serum sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06332157 id: 2023-ke-715-1 briefTitle: Postoperative Quality of Recovery After General Anesthesia With Remimazolam overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2025-12 date: 2025-12 date: 2024-03-27 date: 2024-03-27 name: Beijing Chao Yang Hospital class: OTHER briefSummary: 126 patients undergoing general anesthesia for elective surgery in Beijing Chaoyang Hospital were selected. In the intervention group, anesthesia was induced with remimazolam besylate at a rate of 6mg/min; Anesthesia was maintained with 1.0-2.0mg/min remimazolam besylate by continuous pump. Control group: anesthesia induction, intravenous injection of propofol 2mg/kg; Anesthesia was maintained by continuous pumping of 6-8mg/kg/h propofol. All patients were routinely monitored for vital signs and anesthesia depth after entering the operating room. The patients were followed up after surgery, and the quality of recovery score at 24 hours after surgery was the main study outcome. conditions: Anesthesia Recovery Period studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 126 type: ESTIMATED name: Remimazolam besylate name: Propofol Injection Emulsion measure: 15-item quality of recovery scale sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06332144 id: 1R56DC020208-01A1 type: NIH link: https://reporter.nih.gov/quickSearch/1R56DC020208-01A1 briefTitle: Predicting Language and Literacy Growth in Children With ASD Using Statistical Learning acronym: PLAUSL overallStatus: RECRUITING date: 2024-01-13 date: 2024-08-31 date: 2024-08-31 date: 2024-03-27 date: 2024-03-27 name: Northeastern University class: OTHER name: University of Delaware name: Boston University name: Cornell University briefSummary: The goal of this observational study is to test a reciprocal relationship between statistical learning and the development of language and literacy in first-graders with autism and their non-autistic peers. The main questions it aims to answer are: